PROACTIVE IMMUNE RESPONSE DETECTION

Trinitas is advancing the utilization of biomarker detection technologies to help proactive detect and mitigate patients with a high risk of adverse immune responses to a range of disease states, including COVID-19.  A preventative biomarker analysis using the Trinitas Risk Index can further the accuracy and utility of advanced infection protocols and targeted therapy to improve clinical outcomes.

 

Trinitas brings its foundational research expertise to exploratory partnerships with leaders in the clinical care, data science, and diagnostics industries.